Cannon, T. L., Rothe, M., Garrett-Mayer, E., Chiu, V. K., Hwang, J. J., Vijayvergia, N., … Schilsky, R. L. (2023). Pertuzumab plus trastuzumab (P plus T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. 546–546).

Cannon, Timothy Lewis, Michael Rothe, Elizabeth Garrett-Mayer, Vi Kien Chiu, Jimmy J. Hwang, Namrata Vijayvergia, Olatunji B. Alese, et al. “Pertuzumab plus trastuzumab (P plus T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In JOURNAL OF CLINICAL ONCOLOGY, 41:546–546, 2023.

Cannon TL, Rothe M, Garrett-Mayer E, Chiu VK, Hwang JJ, Vijayvergia N, et al. Pertuzumab plus trastuzumab (P plus T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 546–546.

Cannon, Timothy Lewis, et al. “Pertuzumab plus trastuzumab (P plus T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. 546–546.

Cannon TL, Rothe M, Garrett-Mayer E, Chiu VK, Hwang JJ, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute K, Sahai V, Ahn ER, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES-H, Grantham GN, Halabi S, Schilsky RL. Pertuzumab plus trastuzumab (P plus T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 546–546.